Qingdao Vland Biotech (SHSE:603739) Stock Falls 18% in Past Week as Five-year Earnings and Shareholder Returns Continue Downward Trend
Qingdao Vland Biotech (SHSE:603739) Stock Falls 18% in Past Week as Five-year Earnings and Shareholder Returns Continue Downward Trend
Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly. To wit, the Qingdao Vland Biotech INC. (SHSE:603739) share price managed to fall 60% over five long years. We certainly feel for shareholders who bought near the top. We also note that the stock has performed poorly over the last year, with the share price down 35%. The falls have accelerated recently, with the share price down 30% in the last three months.
一般而言,長期投資是必經之路。但在此過程中,一些股票將表現不佳。也就是說,青島威蘭生物技術有限公司(上海證券交易所代碼:603739)股價在漫長的五年中成功下跌了60%。對於在接近頂部買入的股東,我們當然有同感。我們還注意到,該股去年表現不佳,股價下跌了35%。最近跌勢加速,股價在過去三個月中下跌了30%。
With the stock having lost 18% in the past week, it's worth taking a look at business performance and seeing if there's any red flags.
由於該股在過去一週下跌了18%,值得一看業務表現,看看是否有任何危險信號。
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
儘管一些人繼續教導高效市場假說,但事實證明,市場是反應過度的動態系統,投資者並不總是理性的。研究市場情緒如何隨着時間的推移而變化的一種方法是研究公司股價與其每股收益(EPS)之間的相互作用。
During the five years over which the share price declined, Qingdao Vland Biotech's earnings per share (EPS) dropped by 12% each year. Readers should note that the share price has fallen faster than the EPS, at a rate of 17% per year, over the period. This implies that the market was previously too optimistic about the stock.
在股價下跌的五年中,青島威蘭德生物科技的每股收益(EPS)每年下降12%。讀者應注意,在此期間,股價的下跌速度快於每股收益,每年下降17%。這意味着市場此前對該股過於樂觀。
You can see how EPS has changed over time in the image below (click on the chart to see the exact values).
您可以在下圖中看到 EPS 隨時間推移的變化(點擊圖表查看確切值)。
Dive deeper into Qingdao Vland Biotech's key metrics by checking this interactive graph of Qingdao Vland Biotech's earnings, revenue and cash flow.
查看這張青島威蘭德生物的收益、收入和現金流的交互式圖表,深入了解青島威蘭德生物的關鍵指標。
A Different Perspective
不同的視角
While the broader market lost about 17% in the twelve months, Qingdao Vland Biotech shareholders did even worse, losing 34% (even including dividends). However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 10% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Qingdao Vland Biotech better, we need to consider many other factors. Take risks, for example - Qingdao Vland Biotech has 2 warning signs we think you should be aware of.
儘管整個市場在十二個月中下跌了約17%,但青島Vland Biotech的股東表現更糟,損失了34%(甚至包括股息)。但是,可能只是股價受到了更廣泛的市場緊張情緒的影響。如果有很好的機會,可能值得關注基本面。不幸的是,去年的表現可能預示着尚未解決的挑戰,因爲它比過去五年中10%的年化虧損還要糟糕。總的來說,長期股價疲軟可能是一個壞兆頭,儘管逆勢投資者可能希望研究該股以期出現轉機。長期跟蹤股價表現總是很有意思的。但是,要更好地了解青島威蘭德生物科技,我們需要考慮許多其他因素。例如,冒險吧——青島威蘭德生物科技有兩個警告信號,我們認爲你應該注意。
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
對於那些喜歡尋找中獎投資的人來說,這份最近有內幕收購的成長型公司的免費名單可能只是門票。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。